glp‑1 alcohol reduction

GLP-1 reduces heavy drinking days in treatment seeking people with alcohol use disorder and obesity, finds small trial — Phot

7 Reasons Obesity Treatment Beats Naltrexone for Alcohol

Obesity treatment with GLP-1 drugs reduces heavy drinking, promotes weight loss, and streamlines care more effectively than naltrexone for patients with both obesity and alcohol use disorder. In a 12-week randomized trial, weekly semaglutide cut heavy drinking days by 28% versus placebo, while also producing a 7% average weight loss